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Abstract
Introduction—Women have been reluctant to adopt longer than annual intervals for cervical 
cancer screening, despite guidelines recommending screening every 3 to 5 years. Our study 
assessed patient knowledge and beliefs about human papillomavirus (HPV) and cervical cancer 
screening after exposure to an educational intervention, and whether there was a change in time 
regarding knowledge and beliefs among all study participants in an underserved population.
Method—The study was conducted in 15 clinics associated with 6 Federally Qualified Health 
Centers in Illinois, USA. Cervical cancer screening patients (n = 644) completed a baseline and 
postintervention follow-up survey. The intervention included an HPV test and an educational 
pamphlet. Significance testing of changes in knowledge and beliefs was conducted with 
multilevel, mixed-effects models adjusting for repeated measures of patients and clustering within 
clinics.
Results—No significant differences in study outcomes were found between the intervention and 
control groups. Among all women, knowledge of HPV significantly improved over time. At 
follow-up, fewer women reported that having a co-test is good, wise, will give you peace of mind, 
will tell you whether you need to worry if Pap is abnormal, is something your doctor thinks you 
should have, and will give you the best care available. More women said it would be bad, useless, 
or worrying to wait 3 years for a Pap test at follow-up.
Conclusion—HPV knowledge improved over time, but the educational intervention utilized in 
this study was not successful in improving attitudes and beliefs about co-testing and longer 
screening intervals, and beliefs about HPV co-testing and 3-year screening intervals were less 
favorable. Having health care providers discuss the consequences of overscreening and the natural 
history of HPV and cervical cancer with their patients may help increase adherence to longer 
screening intervals. Further examination of the essential components for educational intervention 
in this population is warranted.
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Introduction
Cervical cancer screening with the Papanicolaou (Pap) test has been the bedrock of women’s 
annual primary care services for decades. Current cervical cancer screening guidelines 
recommend longer screening intervals; women aged 30 to 65 years should have a Pap test 
every 3 years or a human papillomavirus (HPV) co-test (Pap and HPV test) every 5 years.
1-3 
Some women, particularly those without an usual source of care or insurance
4
 are screened 
less often than recommended, which can lead to more disease.
5
 However, many women in 
the United States are screened too frequently; health care providers and patients have been 
slow to accept guidelines that recommend longer than annual intervals between screenings, 
and women, including those who are low-income, are often screened annually.
6-9 For 




 and the 
relation to cervical cancer,
11
 a desire for more frequent care, a higher degree of perceived 
risk of cervical cancer,
12
 and skepticism about cost as the motivation for the guidelines have 
been identified as barriers to extending screening intervals.
9
 Additionally, guidelines for 
cervical cancer screening have been revised twice in the past 6 years (2009 and 2012), and 
these changes may be partially responsible for the resistance to changing screening 
practices. Guidelines are likely to continue to evolve, including the option of HPV testing as 
a primary screening approach.
13
The Centers for Disease Control and Prevention (CDC) launched the CDC Cervical Cancer 
(Cx3) Study, a multicomponent educational intervention designed to increase the willingness 
of health care providers and their medically underserved patients to extend routine cervical 
cancer screening intervals and decrease excessive screening.
14
 The primary purpose of this 
analysis was to assess whether the educational intervention resulted in changes in patients’ 
knowledge and beliefs about HPV and cervical cancer screening. We also examined whether 
there was a change in knowledge and beliefs about HPV and cervical cancer screening 
among all study participants over time.
Method
Study Design
The Cx3 Study was conducted in 15 clinics associated with 6 Federally Qualified Health 
Centers (FQHCs) in Illinois, USA.
14
 All clinics were enrolled in the study by August 2009. 
CDC selected FQHCs as the study site because clients are predominately low-income and 
underinsured or uninsured. Assessing practices in this settings will help CDC provide 
technical assistance to national cancer programs.
Each clinic was assigned to 1 of 2 study groups: intervention (n = 7) or control (n = 8). All 
clinics received HPV tests to be used with the Pap test for cervical cancer screening. Clinics 
in the intervention group received a multicomponent educational program that included 
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educational materials for providers and patients that were designed for this study. For the 
patient participating in the intervention, a 22-page pamphlet and a bookmark promoting the 
HPV co-test and the longer screening interval were developed in English and Spanish. The 
pamphlet was written at a sixth grade reading level. These materials were distributed to 
patients in the intervention group after they completed a baseline survey. Women coming 
into the clinics for routine care were eligible if they were between the ages of 30 and 60 
years at the time of enrollment and scheduled for a regular screening Pap test but were 
excluded if they had an abnormal Pap test in the past year, a history of cervical cancer, or a 
hysterectomy. This study was approved by CDC’s Institutional Review Board, and informed 
consent was obtained from study participants.
Surveys
A baseline survey was completed during 2009-2011 by 984 women aged 30 to 60 years who 
were receiving a regular screening Pap test. Eligible patients were identified through medical 
chart review by clinic staff and were invited to participate when they arrived at the clinic for 
their visit. No records were kept on those who refused participation; thus, we could not 
calculate a response rate for baseline.
6
 Baseline questionnaires were self-administered in the 
clinic waiting room before each woman’s examination and were available in English and 
Spanish. The survey collected information on demographic characteristics, sources of 
information about HPV, knowledge and beliefs about HPV, and beliefs about HPV co-testing 
and longer cervical cancer screening intervals. A follow-up survey was mailed to 
participating women 15 months after the baseline survey. Of the 984 women who completed 
the baseline survey, 644 completed the follow-up survey (response rate 65.4%). Patients 
were offered a $5 cash incentive for participating in each survey. Significant differences 
between respondents and nonrespondents to the follow-up survey related to age 
(nonrespondents were younger), race/ethnicity (patients of Hispanic ethnicity were less 
likely to complete the survey), and insurance coverage (patients with private insurance were 
more likely to respond than those with no insurance).
Measures
The baseline and follow-up surveys included a skip question that asked participants whether 
they had ever heard of HPV (response options: “yes” or “no”). Participants who had never 
heard of HPV were not asked the remaining questions. To assess sources of knowledge 
about HPV, participants were asked to indicate whether they had heard of HPV from 17 
potential sources of health information (Table 1).
HPV knowledge was assessed on the basis of responses to 22 items (Figure 1) after the 
following statement: “We are interested in your opinions and what you may have heard 
about HPV.” Responses were “agree,” “disagree,” and “not sure.” Women who responded to 
one or more of the HPV knowledge items but left other items blank were considered to have 
incorrect knowledge for unanswered items. Women who did not respond to any of the 22 
items but answered other questions on the same page and subsequent pages of the survey 
were considered to have incorrect knowledge to all items. Those who did not respond to any 
of the HPV knowledge items or the adjacent questions were categorized as having missing 
responses.
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Eight items were used to assess participants’ beliefs about HPV co-testing (Table 2). In the 
baseline survey, these items were prefaced with the statement, “Getting an HPV test with the 
Pap test today …” In the follow-up survey, the statement was reworded to, “Getting an HPV 
test the next time you get a Pap test …” Five items were used to assess participants’ beliefs 
and intentions about extending cervical cancer screening intervals to 3 years, which was the 
recommendation at the time of the survey (Table 3).
Statistical Analysis
We compared responses from patients who answered the baseline and follow-up surveys. 
Because we focused on changes in HPV knowledge and beliefs over time, the analytic 
sample was limited to patients with completed follow-up surveys who reported having heard 
of HPV at the time of the survey (baseline survey, n = 511; follow-up survey, n = 496). 
Significance testing of the association of time with knowledge and beliefs was conducted 
with multilevel, mixed-effects, binary and ordinal logistic regression. Models adjusted for 
within-person repeated measures and clustering within clinics as random effects. Because 
participation in the intervention group was not significantly associated with change over 
time, final models included only the main effect of time. Analyses were conducted in Stata 
(version 13.1).
Results
A total of 644 women participated in both the baseline and 15-month follow-up survey. The 
mean age of participants was 46 years; 46% were non-Hispanic white, 27% were Hispanic, 
and 25% were non-Hispanic black. Of this group, 64.4% (n = 415) were from intervention 
clinics and 35.6% (n = 229) were from control clinics. Preliminary analyses comparing 
patients at intervention versus control clinics at baseline revealed no significant differences 
for any of the following study outcomes: reported sources of information, knowledge about 
HPV, beliefs about HPV co-testing, or beliefs about longer screening intervals (data not 
shown). At follow-up, no significant differences in study outcomes were found between the 
intervention and control groups (data not shown, all P values >.05). For all subsequent 
analyses, we combined data from patients at the intervention and control clinics and focused 
on describing changes in all patients’ knowledge and beliefs from baseline to follow-up. At 
baseline, 194 women had not heard of HPV; at follow-up, 28.4% (n = 55) of this group had 
changed to having heard of HPV.
Sources of Information About HPV
Among patients who reported in the baseline survey that they had ever heard about HPV, the 
most common sources of information included television (68%), magazines, (42%), health 
care providers (41%), and pamphlets (33%) (Table 1). At follow-up, the percentage of 
patients reporting health care providers (50%), pamphlets (41%), and the Internet (30%) as 
sources of HPV information increased significantly from baseline. Fewer patients reported 
television as a source of information in the follow-up survey (59%).
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HPV Knowledge and Beliefs
Figure 1 shows participants’ knowledge about HPV at baseline and follow-up and significant 
changes in knowledge over time. At baseline, the highest percentages of correct responses 
were for the following HPV knowledge items: “HPV is a virus” (72%); “There are types of 
HPV that cause cervical cancer” (67%); “You can always tell when someone has HPV” 
(False: 67%); “You can have HPV for a long time without knowing it” (61%). Overall, HPV 
knowledge improved between baseline and follow-up as reflected by significant increases in 
the percentage of correct responses for all HPV knowledge items (P < .05) except “HPV 
may go away by itself.”
Beliefs About Co-Testing and Screening Intervals With the Pap Test
At baseline, participants reported that getting the HPV co-test was good (85%) or wise 
(92%), will give you peace of mind (Agree: 91%), will tell you whether you need to worry if 
Pap is abnormal (Agree: 80%), is something your doctor thinks you should have (Agree: 
70%), and will give you the best care available (Agree: 91%) (Table 2). However, at follow-
up, fewer participants reported that getting the HPV co-test was good (78%, P = .003) or 
wise (86%, P = .002), will give you peace of mind (84%, P < .001), will tell you whether 
you need to worry if Pap is abnormal (71%, P = .001), is something your doctor thinks you 
should have (54%, P < .001), and will give you the best care available (82%, P < .001). For 
all attitude items, “neither/not sure” responses increased.
Table 3 presents participants’ beliefs about extending the cervical cancer screening interval 
to 3 years with the Pap test if recommended by their provider. At baseline, many participants 
reported that it would be bad (53%), useless (53%), or worrying (62%). At follow-up, the 
percentage of patients reporting that the extended interval would be bad (63%, P < .001), 
useless (60%, P = .010), or worrying (66%; P = .027) increased.
Discussion
We hypothesized that low-income women in our study who received an educational 
pamphlet and HPV co-testing would report improved knowledge about HPV and positive 
beliefs about co-testing and longer screening intervals. The major findings from this study 
are (a) there were no differences in knowledge, attitudes or beliefs between the 2 study 
groups; (b) among all women, knowledge of HPV improved between baseline and follow-
up; and (c) among all women, beliefs about the use of the HPV co-test as a screening 
strategy and the extension of screening intervals to 3 years with a Pap test were less 
favorable at follow-up compared with baseline.
In this study population, low knowledge and awareness about cervical cancer screening was 
associated with higher resistance to longer cervical cancer screening intervals.
6
 The 
pamphlet, given to patients at designated intervention sites, included extensive information 
on cervical cancer, cervical cancer screening tests and intervals, and HPV. These materials 
were delivered with the intention of raising awareness of the safety and benefits of HPV co-
testing and longer screening intervals, thereby improving knowledge to facilitate changes in 
attitudes and beliefs. There are multiple possible explanations why the pamphlet used in the 
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study was not successful in changing attitudes and beliefs. While the Community Guide 
recommends small media and one-on-one education as effective strategies for increasing 
cervical cancer screening,
15,16 the Community Guide has not examined these strategies in 
changing knowledge and attitudes for longer screening intervals. Regarding the intervention 
delivery, intervention participants were told to review the pamphlet on their own, and no 
checks were in place to determine whether they read or understood the content. Moreover, 
providers at control sites may have given patients additional information or resources on 
HPV testing and cervical cancer, inadvertently affecting the results. The extent to which 
patients reported that they had learned about HPV from pamphlets and health care providers 
increased from baseline to follow-up for both groups, supporting this theory. Apart from the 
intervention delivery, the lack of significance between the 2 study groups may also be 
related to the content and exposure time. One pamphlet or educational material may not be 
sufficient, and education may need to be delivered over a longer period of time, as opposed 
to a one-time exposure. Results from this study make it clear that effective cervical cancer 
screening interventions are needed to not only increase screening uptake,
17
 but to increase 
awareness and knowledge, address perceptions, and promote adherence to screening 
guidelines,
18
 and additional research is needed to understand the essential core components 
of educational interventions
19,20 targeting screening attitudes and beliefs among low-income 
and medically underserved women.
One positive outcome from this study was the reported overall improvements in HPV 
knowledge among all women, such as HPV can cause cervical cancer and is sexually 
transmitted. However, our analysis found that among women in both the intervention and 
control groups, many of the beliefs about the co-test and longer intervals assessed in the 
surveys worsened over time. This finding is particularly surprising, and could be an 
unintended consequence of the intervention and messaging. The desire for more frequent 
care
9
 and a high degree of worry, and overestimation of risk for cervical cancer
6,9,12,21 are 
real concerns for women and may be driving preferences for more-frequent screening. 
Recommendations for longer screening intervals and frequent changes in recommendations 
could be particularly disconcerting for women who perceive themselves to be at higher risk 
of cancer. Education does improve knowledge, but alone does not necessarily allay fears of 
cervical cancer
22
 or increase willingness to extend screening intervals,
7
 as results of our 
study demonstrate. The intervention was not significant in changing attitudes and beliefs, 
and some beliefs actually worsened. As such, health care providers have a key role in clearly 
communicating individual risk and the natural history of HPV and cervical cancer, as well as 
the potential harms of excessive screening, which may help reduce their patients’ anxiety 
and increase acceptance of and adherence to longer intervals.
21,23 At baseline, only 11% of 
women reported previously receiving guidance from their providers to return for a routine 
Pap test in 2 or 3 years, and the recommendation actually received by most of the women in 
our study had been to undergo annual Pap testing. It has been well established that physician 
recommendation is an important influence on patient behavior; without change to the 
provider’s screening intervals recommendations, significant change in Pap testing practices 
and attitudes are unlikely.
6
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Clinics that participated in the study are not necessarily representative of all FQHCs in 
Illinois, thus, our results may not be generalizable. Regarding delivery of the educational 
intervention, we did not measure whether patients in the intervention group were actually 
exposed to the educational pamphlet or whether patients in the control group may have 
received the pamphlet or other materials from their providers. At follow-up, 41% of patients 
in the intervention group and 42% of those in the control group reported pamphlets as a 
source of HPV information. In addition, the population served by FQHCs may have low 
health literacy affecting their ability to understand patient education materials.
24
 Also, 
patients in both the intervention and control groups received HPV tests during routine 
screening. Receiving the HPV test may have constituted an intervention of its own, 
contributing to the increase in knowledge. However, because our study did not include a 
sample of women who did not receive the HPV test at baseline, we cannot measure the 
effect of the test on knowledge outcomes. Finally, exposure to the baseline survey that 
included HPV and cervical cancer-related content may have affected follow-up survey 
responses.
In summary, there were no significant differences in knowledge, attitudes, and beliefs 
between the intervention and control groups. HPV knowledge and beliefs of the medically 
underserved women in this study improved over time, however, resistance to the HPV co-
test and longer screening intervals persisted through the study, and beliefs about co-testing 
and longer intervals worsened over time. Findings from our intervention study highlight that 
HPV and cervical cancer screening are complex topics, and require intensive intervention 
methods, especially among medically underserved women. Whether women in FQHCs are 
being screened too frequently, or are rarely or never screened, appropriate implementation of 
screening according to guidelines would increase the quality of cervical cancer prevention 
services for all women, including those at-risk for developing cervical cancer. To achieve 
appropriate screening, interventions will need to target not only provider and patient 
attitudes and beliefs, but larger systems barriers to ensure equitable distribution of cervical 
cancer screening resources.
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Percentage of study participants who responded to human papillomavirus (HPV) knowledge 
items correctly, baseline and 15-month follow-up survey. Study was conducted in 15 
Federally Qualified Health Center clinics in Illinois, USA. Baseline surveys were conducted 
during 2009-2011; follow-up surveys were conducted during 2011-2012.Note. (F) = item is 
false; correct response was “disagree.” P values were calculated with multilevel, mixed-
effects, binary logistic regression models and adjusted for repeated measures of patients and 
clustering within clinics as random effects. Sample includes patients who had ever heard of 
HPV. Baseline survey, n = 480; follow-up survey, n = 486. Significant differences by survey: 
***P < .001; **P < .01; *P < .05.
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Table 1
Participant Responses to Sources of Human Papillomavirus (HPV) Information, Baseline and 15-Month 
Follow-up Surveys.
a




Baseline (n = 483) Follow-up (n = 493)
% n % n P 
c
Television 68 330 59 290 <.001
Magazines 42 201 40 196 .603
Health care provider 41 196 50 245 .002
Pamphlets 33 159 41 204 .003
Internet 25 123 30 146 .032
Health department 24 115 26 130 .205
Friends 23 111 26 128 .157
Family 21 103 23 111 .781
Radio 19 91 17 84 .505
Medical books/medical journals 17 83 16 80 .603
Family planning clinics 12 58 12 57 .875
Books 12 57 11 52 .446
Coworkers 11 52 11 56 .640
Planned Parenthood 5 25 5 24 .756
Partner 4 19 3 17 .623
Teacher 3 16 3 13 .480
Telephone hotline 1 3 1 3 .985
a
Study was conducted in 15 Federally Qualified Health Center clinics in Illinois, USA. Baseline surveys were conducted during 2009-2011; 
follow-up surveys were conducted during 2011-2012.
b
Sample of patients who had ever heard of HPV.
c
P values were calculated with multilevel, mixed effects, binary logistic regression models and adjusted for repeated measures of patients and 
clustering within clinics as random effects.
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Table 2
Participant Responses to Statements About the Human Papillomavirus (HPV) Co-Test, Baseline and 15-Month 
Follow-up Surveys.
a
Baseline Statement: “Getting an HPV with Pap test today




Follow-up statement: “Getting an HPV test the next time
you get a Pap test …”
b % n % n OR P
Good or bad Bad 0 1 1 5 0.55
.003
d
Neither 15 70 21 100
Good 85 409 78 380
Useful or useless Useless 24 116 21 101 0.94 .723
Neither 5 22 11 54
Useful 71 337 68 328
Comforting or worrying Worrying 11 55 9 42 1.19 .279
Neither 23 111 25 121
Comforting 66 316 67 324
Wise or foolish Foolish 0 2 2 11 0.48
.002
e
Neither 8 37 12 58
Wise 92 437 86 415
Will give you peace of mind Disagree 1 3 3 16 0.38
<.001
f
Neither/Not sure 8 39 13 61
Agree 91 442 84 410
Will tell you whether you need to
 worry if Pap is abnormal
Disagree 4 19 9 42 0.54 .001
Neither/Not sure 16 77 20 95
Agree 80 374 71 341
Is something doctor thinks you
 should have
Disagree 5 25 10 50 0.41 <.001
Neither/Not sure 25 117 36 172
Agree 70 325 54 260
Will give you the best care available Disagree 1 5 3 16 0.29 <.001
Neither/Not sure 8 37 15 73
Agree 91 431 82 394
a
Study was conducted in 15 Federally Qualified Health Center clinics in Illinois, USA. Baseline surveys were conducted during 2009-2011; 
follow-up surveys were conducted during 2011-2012.
b
Sample of patients who ever heard of HPV.
c
P values were calculated with multilevel, mixed-effects regression models and adjusted for repeated measures and clustering within clinics as 
random effects. Models were run with ordinal logistic regression except where noted.
d
Options “Bad” and “Neither” were combined and tested with binary logistic regression.
e
Options “Foolish” and “Neither” were combined and tested with binary logistic regression.
f
Options “Disagree” and “Neither” were combined and tested with binary logistic regression.
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Table 3
Participant Responses to Questions About Extending the Screening Interval to 3 Years With the Pap Test, 
Baseline and 15-Month Follow-up Surveys.
a,b




% n % n OR P
If your health care provider recommends that
 you have your next Pap test in 3 years, how
 likely are you to wait that long?
Unlikely 58 277 58 284 1.03 .822
Neither 8 36 6 27
Likely 34 164 36 177
How good or bad would it be to wait 3 years for
 your next Pap test if that is what your health
 care provider recommends that you do?
Bad 53 256 63 308 0.57 <.001
Neither 15 73 13 62
Good 32 154 24 120
How useless or useful would it be to wait 3
 years for your next Pap?
Useless 53 251 60 290 0.69 .010
Neither 21 98 20 98
Useful 27 12 20 99
How comforting or worrying would it be to
 wait 3 years for your next Pap?
Worrying 62 298 66 325 0.71 .027
Neither 18 86 18 90
Comforting 20 97 15 74
How wise or foolish would it be to wait 3 years
 for your next Pap?
Foolish 63 301 67 327 0.80 .124
Neither 19 91 19 92
Wise 18 87 15 72
a
Study was conducted in 15 Federally Qualified Health Center clinics in Illinois, USA. Baseline surveys were conducted in 2009-2011, follow-up 
surveys were conducted 2011-2012.
b
sample of patients who completed follow-up survey and ever heard of HPV.
c
Multilevel mixed effects modeling with ordinal logistic models adjusting for within person repeated measures and clustering within clinic as 
random effects.
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